|
| Status |
Public on Mar 31, 2016 |
| Title |
DV90_Vehicle_DMSO_24h_rep4 |
| Sample type |
RNA |
| |
|
| Source name |
DV90 cells vehicle, DMSO, 24h
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: lung
cell line: DV90
histologic subtype: NSCLC adenocarcinoma
|
| Treatment protocol |
DV90 cells were seeded on the day before treatment and treated with 135 nM or 785 nM of JQ1 (BET inhibitor) or DMSO (vehicle control) for 4h or 24h.
|
| Growth protocol |
Human Lung Cell line , NSCLC adenocarcinoma, DV90 from Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) was cultured using RPMI1640 medium (Biochrom) supplemented with 10% fetal calve serum (Biochrom) and non-essential amino acids (Biochrom)
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was extracted using RNeasy Plus Mini kit (Qiagen).
|
| Label |
biotin
|
| Label protocol |
For each sample, 250ng of total RNA was amplified using the Affymetrix GeneChip WT PLUS Reagent Kit according to the protocol described in User Manual Target Preparation for GeneChip Whole Transcript (WT) Expression Arrays (P/N 703174 Rev. 2)
|
| |
|
| Hybridization protocol |
An Affymetrix Human Gene 2.1 ST 96-array plate was hybridized with 3μg of fragmented and labeled ss cDNA, washed, stained, and scanned according to the protocol described in the User Manual GeneTitan®Instrument User Guide for Expression Array Plates (P/N 702933 Rev.1) and Affymetrix® GeneChip® Command Console™ User’s Guide (P/N 702569 Rev.9) using the Affymetrix GeneTitan instrument
|
| Scan protocol |
Array plates were scanned using Affymetrix GeneTitan, AGCC 4.2.0
|
| Description |
gene expression data from DV90 cells vehicle, DMSO, 24h
|
| Data processing |
Genedata Refiner Array software was used to process the cel files. Antigenomic background probes were used for background subtraction before quantile normalization. RMA algorithm was used to aggregate the probe sets on a meta probe set level. Resulting values were shifted to mean value of 100 and further normalized using LOWESS normalization.
|
| |
|
| Submission date |
Dec 14, 2015 |
| Last update date |
Mar 31, 2016 |
| Contact name |
Ralf Lesche |
| E-mail(s) |
ralf.lesche@bayer.com
|
| Organization name |
Bayer Pharma AG
|
| Street address |
Muellerstr 178
|
| City |
Berlin |
| ZIP/Postal code |
13342 |
| Country |
Germany |
| |
|
| Platform ID |
GPL17692 |
| Series (1) |
| GSE75960 |
Expression data from non-small cell lung cancer cell line DV90 after Bromodomain and extra terminal domain (BET) inhibitor JQ1 treatment |
|
